Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Treating EGFR-mutated lung cancer just got more nuanced. Experts at a recent oncology workshop agreed that while TP53 comutations signal higher risk, they shouldn't automatically trigger chemotherapy combinations — patient age, disease burden, and personal priorities matter just as much. Meanwhile, sunvozertinib, newly available in the U.S., is offering a fresh option for a hard-to-treat EGFR mutation subtype.
Oncologists are wrestling with increasingly complex treatment decisions for EGFR-mutated non-small cell lung cancer (NSCLC), and a recent expert workshop made clear there's no one-size-fits-all answer. While phase 3 data from the FLAURA2 and TOP trials confirm that adding chemotherapy to osimertinib improves progression-free survival — especially in patients with concurrent TP53 mutations — faculty emphasized that TP53 status alone shouldn't drive frontline therapy. Factors like age, comorbidities, disease burden, and patient preferences can outweigh genomic risk signals.
Long-term safety data are also reshaping how clinicians weigh their options. In FLAURA2, 43% of patients experienced grade 3+ toxicities during induction, and a third discontinued pemetrexed due to side effects. The amivantamab-lazertinib combination has shown improved toxicity profiles with subcutaneous delivery and enhanced supportive care — but persistent issues like paronychia remain difficult to manage, and the overall treatment burden is considerable.
On the EGFR exon 20 insertion front, sunvozertinib (Zegfrovy) became available in the U.S. in October 2026 after receiving FDA accelerated approval in July 2025, offering a new option for previously treated patients.
Key Takeaways
Why it matters: As EGFR+ NSCLC treatment options expand, the challenge is no longer just finding effective therapies — it's matching the right regimen to the right patient while managing a growing toxicity burden. These discussions signal a shift toward more individualized, patient-centered decision-making in thoracic oncology.
